Press release
Investigation announced for Investors in Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) over potential Wrongdoing
An investigation on behalf of investors in Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) shares over potential wrongdoing.
Investors who purchased shares of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Eiger BioPharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
Palo Alto, CA based Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally.
On September 6, 2022, Eiger BioPharmaceuticals, Inc. provided an update on the status of its planned request for emergency use authorization (EUA) of peginterferon lambda. Following a cooperative and extensive pre-EUA information exchange with FDA regarding the Phase 3 TOGETHER study of peginterferon lambda for COVID-19, the agency has indicated that it is not yet able to determine whether the criteria for the submission of an application and issuance of an EUA are likely to be met. FDA has indicated that it will consider any new information and data from the TOGETHER study to support a EUA as well as the company's plans for the further development of peginterferon lambda for COVID-19. Eiger BioPharmaceuticals, Inc. said that it remains in active dialogue with FDA and will provide additional information to the agency that the company believes could be supportive of a EUA.
Shares of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) declined from $9.89 per share on August 16, 2022, to as low as $4.54 per share on November 3, 2022.
Those who purchased shares of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) over potential Wrongdoing here
News-ID: 2792126 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Eiger
Hutchinson-Gilford Progeria Syndrome Market Expected to Reach Rapid Growth by 20 …
Global Hutchinson-Gilford progeria syndrome market reached to reach at a significant CAGR during the forecast period 2024-2031.
Hutchinson-Gilford Progeria Syndrome Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive…
Post-Bariatric Hypoglycemia Market Expected to rise, 2034 | Vogenx, Eiger BioPha …
The Post-Bariatric Hypoglycemia market growth is driven by factors like increase in the prevalence of Post-Bariatric Hypoglycemia, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Post-Bariatric Hypoglycemia market report [https://www.delveinsight.com/report-store/post-bariatric-hypoglycemia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Post-Bariatric Hypoglycemia market size, share, Post-Bariatric Hypoglycemia epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and…
Hutchinson-Gilford Progeria Syndrome Market Forecasted for Major Expansion by 20 …
The Hutchinson-Gilford Progeria Syndrome Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize on these opportunities. Overall, the Hutchinson-Gilford Progeria Syndrome market report is an essential resource for market participants who are looking to gain a comprehensive understanding of the market and identify opportunities for…
Hutchinson Gilford Progeria Syndrome Market Anticipated to Show Positive Growth …
DataM Intelligence has released a new research report on the Hutchinson Gilford Progeria Syndrome market. The report provides a detailed analysis of current and emerging trends, offering insights into the market dynamics. It utilizes Porter's Five Forces model to assess key factors such as supplier and customer relationships, risks from various agents, competitive intensity, and opportunities for new entrants. The study also includes research data from various companies, analyzing factors…
Post Bariatric Hypoglycemia Market Report 2032: Epidemiology Data, Pipeline Ther …
DelveInsight's "Post Bariatric Hypoglycemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Post Bariatric Hypoglycemia, historical and forecasted epidemiology as well as the Post Bariatric Hypoglycemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Post Bariatric Hypoglycemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Post Bariatric Hypoglycemia…
Investigation announced for Long-Term Investors in shares of Eiger BioPharmaceut …
An investigation was announced for current long-term investors in shares of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) concerning potential breaches of fiduciary duties by certain directors of Eiger BioPharmaceuticals, Inc..
Investors who are current long term investors in Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors…
